Oscar Health, Inc.
Long

OSCR: back to support and now it’s decision time

264
After the recent impulse move, OSCR has pulled back to a key support zone around 13.65. That area aligns with the 0.79 Fib retracement, a horizontal level from spring, and a rising trendline that has already triggered reversals in the past. The structure is still intact, and buyers are testing the level again. If support holds and we get a bullish confirmation, the next target is 17.01, followed by a potential breakout toward the high at 22.81.

Volume remains elevated, the overall structure is healthy, and the correction is controlled. A break below 13.00 would invalidate the setup - until then, it’s a clean, high-reward zone with tight risk.

Fundamentally, Oscar Health has revised its 2025 guidance: revenue is expected in the $12–12.2B range, with operating losses projected between $200M and $300M. Despite softening topline growth, earnings per share are improving, and investor sentiment has been shifting. Technical strength is also reflected in the recent rise in RS Rating to 93, confirming that the stock is showing relative leadership even as the market cools.

This is one of those setups where both technicals and narrative are aligning - now we just need confirmation from the chart.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.